US Patent 6,153,635: Scope of Claims and US Landscape for Combined Intravaginal and Topical Miconazole Nitrate in Vulvovaginal Candidiasis
US Drug Patent 6,153,635 claims a specific regimen for vulvovaginal candidiasis that combines (i) a single intravaginal dose of miconazole nitrate and (ii) topical vulvar application of miconazole nitrate. The claim set is tight on route, dose form concept (cream/percent-adapted amounts), and treatment frequency/duration for the topical component.
What do the independent claims cover? (Claim 1 and Claim 8)
Claim 1: method of treatment with a single intravaginal dose plus topical vulvar dosing
Claim 1 is a method claim with “consisting essentially of” language, which limits additional steps beyond the two specified. It requires both:
- Intra-vaginal administration
- “administering a single dose of an effective amount of miconazole nitrate in a pharmaceutically acceptable carrier intra-vaginally”
- Topical vulvar application
- “applying topically miconazole nitrate in a pharmaceutically acceptable carrier to the vulva”
The claim language does not require specific product brands or named dosage forms beyond what is supplied via dependent claims (percent creams/grams). The core novelty framing is the two-site dosing architecture: single dose intravaginally plus separate topical vulvar treatment.
Claim 8: kit with a single intravaginal dose component plus a vulvar topical amount
Claim 8 is a kit claim with the same structure, “consisting essentially of,” containing:
- A single dose of effective miconazole nitrate in a carrier “in a form adapted to be administered intra-vaginally”
- An amount of miconazole nitrate in a carrier adapted for topical vulvar application
This claim covers commercial packaging where the intravaginal and vulvar components are supplied together as a coordinated regimen.
How narrow is the dose and schedule coverage? (Key dependent claim parameters)
The dependent claims calibrate the intravaginal dose range and define the topical dosing schedule and duration.
Intravaginal single-dose miconazole nitrate amount
- Claim 2: intravaginal single dose is about 400 mg to about 2000 mg miconazole nitrate
- Claim 3: intravaginal single dose is about 600 mg to about 1200 mg
- Claim 4: specific cream/percent dosing equivalencies:
- 2.5 g of 16% miconazole nitrate cream, or
- 5 g of 8% miconazole nitrate cream, or
- 5 g of 12% miconazole nitrate cream, or
- 5 g of 16% miconazole nitrate cream
Interpretation for product design and infringement mapping: Claim 4 ties the regimen to commercially plausible cream strengths and gram amounts, creating clearer entry points for generic or reformulated versions that match those percent/grams relationships.
Topical vulvar dosing frequency and duration
- Claim 5: vulva application 1–2 times per day
- Claim 6: vulva application 1–2 times per day for about 7 days
- Claim 7: Claim 3’s intravaginal dose range paired with the same topical schedule:
- 1–2 times per day for about 7 days
Interpretation: These claims operationalize the topical component into a defined course length (about 7 days), which narrows “off-calendar” topical regimens.
Kit dependent claims track the method numerics
- Claim 9: kit intravaginal single dose about 400–about 2000 mg
- Claim 10: kit intravaginal single dose about 600–about 1200 mg
- Claim 11: kit intravaginal component includes the same cream/percent gram options as Claim 4
- Claim 12: kit includes a topical amount sufficient for 1–2 times/day for about 7 days
- Claim 13: kit includes the same topical schedule paired to Claim 10’s intravaginal dose
What is the effective “technical boundary” of the claims? (Route, dosage architecture, and limitations)
1) Two-site exposure is mandatory
The claims require both:
- intravaginal dosing, and
- vulvar topical dosing.
A product that uses only intravaginal miconazole nitrate at a single dose does not meet the literal structure of Claim 1. Likewise, a topical-only strategy does not meet Claim 1.
2) The intravaginal dose is a single-dose concept
“single dose” is explicit. Regimens that use multiple intravaginal applications over several days are outside Claim 1’s literal scope, absent equivalence doctrines.
3) The regimen is paired with a about-7-day vulvar schedule (when dependent claims are asserted)
Even if a competitor matches the single intravaginal dose architecture, matching Claim 6 or Claim 12 requires the vulvar application schedule to be 1–2 times/day for about 7 days.
4) “Consisting essentially of” limits additional steps
The “consisting essentially of” framing is material. It permits only additional steps that do not materially change the basic and novel feature of the claims (the dual route single-dose intravaginal + topical vulva approach). It reduces room for a challenger to broaden scope by adding other therapeutic steps.
Potential infringement targets: how products can land inside or outside the claim set
Inside the claim language (typical match pattern)
A product or regimen likely falls within Claim 1/8 when it:
- delivers miconazole nitrate intravaginally as a single dose (within the effective range, and especially within the 400–2000 mg or 600–1200 mg dependent ranges), and
- also supplies miconazole nitrate for vulvar topical application, with topical schedule either 1–2/day or 1–2/day for about 7 days for dependent coverage.
Outside the literal claim (typical mismatch pattern)
It likely falls outside when it:
- splits intravaginal dosing into multiple administrations, or
- uses non-miconazole actives for either intravaginal or vulvar sites, or
- limits vulvar topical duration to something materially less than about 7 days (where dependent claims matter).
Patent landscape: what surrounds this claim strategy in the US market
1) The claims are limited to miconazole nitrate
The regimen is actives-specific: miconazole nitrate. That narrows the competitive space relative to broader antifungal combination patents.
2) The claim structure targets a “single-dose intravaginal + topical vulva” regimen
This is a dosing-method and kit architecture rather than a new chemical entity. It overlaps with a common late-20th-century US approach where patents cover:
- dosage regimens,
- dosage forms (e.g., creams with defined strengths),
- combination kits containing multiple dosage forms.
3) Practical relevance to generics
If a generic company markets intravaginal miconazole nitrate as a single-dose formulation, they still face method/kit exposure if their label and packaging also require a vulvar topical miconazole nitrate course that matches the schedule.
Claim scope mapping table (what each dependent claim adds)
| Claim |
What it adds to Claim 1/8 baseline |
Key parameters |
| 2 |
Intravaginal dose range |
~400 mg to ~2000 mg miconazole nitrate (single dose) |
| 3 |
Intravaginal narrower range |
~600 mg to ~1200 mg miconazole nitrate (single dose) |
| 4 |
Specific cream percent/gram options |
2.5 g of 16% OR 5 g of 8%, 12%, 16% miconazole nitrate cream |
| 5 |
Topical frequency |
vulvar application 1–2 times/day |
| 6 |
Topical duration |
vulvar application 1–2 times/day for about 7 days |
| 7 |
Combination of Claim 3 with schedule |
intravaginal ~600–~1200 mg + topical 1–2 times/day for about 7 days |
| 9 |
Kit intravaginal broad range |
~400–~2000 mg single-dose component |
| 10 |
Kit intravaginal narrow range |
~600–~1200 mg single-dose component |
| 11 |
Kit intravaginal cream percent/grams |
2.5 g of 16% OR 5 g of 8%, 12%, 16% |
| 12 |
Kit topical schedule sufficiency |
topical amount for 1–2 times/day about 7 days |
| 13 |
Kit combination |
intravaginal ~600–~1200 mg + topical 1–2 times/day about 7 days |
Business implications for R&D and freedom-to-operate decisions
A. Regimen design pressure points
If you are developing a product intended to compete in vulvovaginal candidiasis with miconazole nitrate, the pressure points are:
- Does the intravaginal regimen qualify as a single dose?
- Does the regimen include a vulvar topical component of miconazole nitrate?
- Does the vulvar topical course run about 7 days and at 1–2 times/day?
B. Kit format risk
If packaging includes both an intravaginal single-dose component and a vulvar topical component in the same “kit,” it aligns with Claim 8 and dependent kit claims. Even if the method claim is managed through labeling, kit claims can still create exposure when the commercial product is assembled as defined.
C. Competitive differentiation by schedule and dosing partition
Competitive products can reduce risk by:
- changing the intravaginal regimen from single-dose to multi-dose, or
- shortening vulvar topical duration materially away from about 7 days, or
- separating the products so the commercial offering does not function as a combined kit embodying Claim 8.
Key Takeaways
- US 6,153,635 claims a dual-route regimen for vulvovaginal candidiasis using miconazole nitrate: single intravaginal dose plus miconazole nitrate topical application to the vulva.
- Dependent claims define the intravaginal single dose numeric ranges (notably ~400–~2000 mg and ~600–~1200 mg) and map to cream strengths/grams (e.g., 2.5 g of 16%; 5 g of 8%, 12%, or 16%).
- The vulvar topical component is constrained to 1–2 times/day, with about 7 days central to multiple dependent claims.
- The kit claim tracks the method numerics and structure, creating exposure not only for regimens but also for packaged combinations.
FAQs
-
Does Claim 1 cover intravaginal miconazole nitrate alone?
No. Claim 1 requires both intravaginal administration and topical application to the vulva.
-
Is the intravaginal miconazole nitrate dosing required to be “single dose” by the claim language?
Yes. “single dose” is an explicit requirement in Claim 1 and Claim 8.
-
What intravaginal dose ranges are explicitly claimed in dependent claims?
Claim 2 covers ~400–~2000 mg; Claim 3 covers ~600–~1200 mg of miconazole nitrate for the intravaginal single dose.
-
How is vulvar dosing frequency and duration defined?
Claim 5 defines 1–2 times per day; Claim 6 defines 1–2 times per day for about 7 days.
-
Does Claim 8 create kit protection matching the method dose architecture?
Yes. Claim 8 covers a kit that includes a single-dose intravaginal miconazole nitrate component plus a vulvar topical miconazole nitrate amount sufficient for the defined schedule in dependent kit claims.
References
[1] Provided claim text for US Patent 6,153,635 (as stated in the prompt).
